Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Elinzanetant in Participants With Impaired Hepatic Function (Classified as Child-Pugh A or B) in Comparison to Matched Controls With Normal Hepatic Function.

NCT04903821 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04903821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04903821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Elinzanetant in Participants With Impaired Hepatic Function (Classified as Child-Pugh A or B) in Comparison to Matched Controls With Normal Hepatic Function.
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
June 1, 2021
Completion date
March 15, 2022
Enrollment
33 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

vasomotor symptoms as a sex hormone-dependent disorder in women and men